On the Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma, BGJ398 showed 18.8% overall response rate and 83.3% disease control rate in patients carrying FGFR2 fusion with manageable toxicities actively supporting its further biologic and clinical investigation24. Here, FGFR2 is linked to cholangiocarcinoma.